##ANALYSISTYPE=SOMATIC_PAIR
##PIPELINE=megSAP 0.1-1143-gd053876
##SAMPLE=<ID=FO00000x02_01,Gender=n/a,ExternalSampleName=272 T 17751/15,IsTumor=yes,IsFFPE=yes,DiseaseGroup=n/a,DiseaseStatus=n/a>
##SAMPLE=<ID=FO00000x01_01,Gender=n/a,ExternalSampleName=272 N 17751/15,IsTumor=no,IsFFPE=yes,DiseaseGroup=n/a,DiseaseStatus=n/a>
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - variant quality (QUAL), depth (DP), allele frequency (AF), mean mapping quality of alternate allele (MQM).
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=regulatory=Regulatory consequence details.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in 1000 genomes project.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD project.
##DESCRIPTION=gnomAD_hom_hemi=Homoyzgous counts and hemizygous counts of gnomAD project (genome data).
##DESCRIPTION=gnomAD_sub=Sub-population allele frequenciens (AFR,AMR,EAS,NFE,SAS) in gnomAD project.
##DESCRIPTION=ESP_sub=Sub-population allele frequency (EA,AA) in NHLBI Exome Sequencing project.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=Sift=Sift effect prediction and score for each transcript: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen=PolyPhen (humVar) effect prediction and score for each transcript: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=fathmm-MKL=fathmm-MKL score (for coding/non-coding regions). Deleterious threshold > 0.5.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 10-20.
##DESCRIPTION=REVEL=REVEL pathogenicity prediction score. Deleterious threshold > 0.5.
##DESCRIPTION=MaxEntScan=MaxEntScan splicing prediction (reference bases score/alternate bases score).
##DESCRIPTION=GeneSplicer=GeneSplicer splicing prediction (state/type/coordinates/confidence/score).
##DESCRIPTION=dbscSNV=dbscSNV splicing prediction (ADA/RF score).
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample FO00000x02_01).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample FO00000x02_01).
##DESCRIPTION=normal_af=Mutant allele frequency in normal (Sample FO00000x01_01).
##DESCRIPTION=normal_dp=Normal depth (Sample FO00000x01_01).
##DESCRIPTION=NGSD_som_c=Somatic variant count in the NGSD.
##DESCRIPTION=NGSD_som_p=Project names of project containing this somatic variant in the NGSD.
##DESCRIPTION=NGSD_hom=Homozygous variant count in NGSD.
##DESCRIPTION=NGSD_het=Heterozygous variant count in NGSD.
##DESCRIPTION=NGSD_group=Homozygous / heterozygous variant count in NGSD with the same disease group (empty because group is n/a).
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validation=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Variant comments from the NGSD.
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, gnomAD o/e scores).
##FILTER=LowDepth=Tumor or normal sample read depth at this locus is below 2
##FILTER=LowEVS=Somatic Empirical Variant Score (SomaticEVS) is below threshold
##FILTER=all-unknown=Allele unknown
##FILTER=depth-nor=Sequencing depth in normal is too low (< 20)
##FILTER=depth-tum=Sequencing depth in tumor is too low (< 20)
##FILTER=freq-nor=Allele frequency in normal > 0.17 * allele frequency in tumor
##FILTER=freq-tum=Allele frequency in tumor < 0.05
##FILTER=lt-3-reads=Less than 3 supporting tumor reads
##FILTER=off-target=Variant marked as 'off-target'.
##FILTER=special-chromosome=Special chromosome
#chr	start	end	ref	obs	tumor_af	tumor_dp	normal_af	normal_dp	filter	quality	gene	variant_type	coding_and_splicing	regulatory	OMIM	ClinVar	HGMD	RepeatMasker	dbSNP	1000g	gnomAD	gnomAD_hom_hemi	gnomAD_sub	ESP_sub	phyloP	Sift	PolyPhen	fathmm-MKL	CADD	REVEL	MaxEntScan	GeneSplicer	dbscSNV	COSMIC	NGSD_som_c	NGSD_som_p	NGSD_hom	NGSD_het	NGSD_group	classification	classification_comment	validation	comment	gene_info
chr1	93303156	93303156	C	T	0.1674	494	0.0000	165		QUAL=156	RPL5	missense	RPL5:ENST00000370321:missense_variant:MODERATE:exon6/8:c.671C>T:p.Ser224Phe:PF14204	regulatory_region_variant:promoter	603634 [RPL5 Diamond-Blackfan anemia 6,612561,Autosomal dominant];										7.5720	D(0.03)	B(0.43)	0.96,0.97	23.70	0.49					0		0	0						RPL5 (inh=AD oe_syn=1.04 oe_mis=0.59 oe_lof=0.00)
chr1	152058833	152058833	G	A	0.1556	2310	0.0000	160		QUAL=164	TCHHL1	missense	TCHHL1:ENST00000368806:missense_variant:MODERATE:exon3/3:c.1325C>T:p.Ser442Phe:												3.2150	D(0.00)	D(0.95)	0.46,0.53	22.90	0.13				COSM1688546,COSM895968	0		0	0						TCHHL1 (inh=n/a oe_syn=1.18 oe_mis=1.05 oe_lof=0.00)
chr1	158585034	158585034	G	T	0.1740	1444	0.0000	100		QUAL=126	SPTA1	missense	SPTA1:ENST00000368147:missense_variant:MODERATE:exon48/52:c.6760C>A:p.His2254Asn:PF00435	regulatory_region_variant:CTCF_binding_site	182860 [SPTA1 Elliptocytosis-2,130600,Autosomal dominant/Pyropoikilocytosis,266140,Autosomal recessive/Spherocytosis,type 3,270970,Autosomal recessive];										8.9920	D(0.00)	D(1.00)	0.99,0.99	28.70	0.34					0		0	0						SPTA1 (inh=AR+AD oe_syn=1.16 oe_mis=1.16 oe_lof=0.39)
chr1	186643823	186643823	G	T	0.1302	2213	0.0000	186		QUAL=144	PTGS2	missense	PTGS2:ENST00000367468:missense_variant:MODERATE:exon10/10:c.1477C>A:p.Leu493Ile:PF03098												3.8700	T(0.10)	P(0.70)	0.91,0.95	23.30	0.28					0		0	0						PTGS2 (inh=n/a oe_syn=1.12 oe_mis=0.61 oe_lof=0.10)
chr1	206646615	206646615	G	A	0.1721	964	0.0000	66		QUAL=100	IKBKE	synonymous,intron	IKBKE:ENST00000367120:synonymous_variant:LOW:exon3/22:c.45G>A:p.Leu15=:PF00069,IKBKE:ENST00000537984:intron_variant:MODIFIER:exon2/20:c.-168-1059G>A::												1.8850			0.81,0.92	11.37						0		0	0						IKBKE (inh=n/a oe_syn=0.91 oe_mis=0.72 oe_lof=0.27)
chr1	219991344	219991344	G	A	0.1431	624	0.0000	294		QUAL=195		intergenic	::intergenic_variant:MODIFIER::::						rs200604309						-0.5770			0.01,0.12	9.49						0		0	0						 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)
chr2	48033789	48033789	C	T	0.1455	276	0.0000	127		QUAL=124	MSH6,FBXO11	missense&splice_region,intron	MSH6:ENST00000234420:missense_variant&splice_region_variant:MODERATE:exon9/10:c.4000C>T:p.Arg1334Trp:,FBXO11:ENST00000405808:intron_variant:MODIFIER:exon3/3:c.169+1545G>A::,MSH6:ENST00000538136:missense_variant&splice_region_variant:MODERATE:exon9/10:c.3094C>T:p.Arg1032Trp:,MSH6:ENST00000540021:missense_variant&splice_region_variant:MODERATE:exon7/8:c.3610C>T:p.Arg1204Trp:		600678 [MSH6 Colorectal cancer,hereditary nonpolyposis,type 5,614350,Autosomal dominant/Endometrial cancer,familial,608089/Mismatch repair cancer syndrome,276300,Autosomal recessive],607871 [FBXO11 Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities,618089,Autosomal dominant];	184389 [uncertain significance DISEASE=Hereditary nonpolyposis colon cancer,Hereditary cancer-predisposing syndrome,Hereditary nonpolyposis colorectal cancer type 5,not specified,not provided];			rs773763465		0.0001	0,.	0.0001,0.0001,0.0000,0.0001,0.0001		2.8010	D(0.00), ,D(0.00),D(0.00)	D(0.95), ,D(0.95),D(0.94)	0.87,0.95	33.00	0.66	6.25>4.27		0.129/0.324	COSM1291512	0		0	0						MSH6 (inh=AR+AD oe_syn=1.47 oe_mis=1.28 oe_lof=0.35), FBXO11 (inh=AD oe_syn=1.25 oe_mis=0.43 oe_lof=0.02)
chr2	141457909	141457909	C	T	0.1205	874	0.0000	271		QUAL=170	LRP1B	missense	LRP1B:ENST00000389484:missense_variant:MODERATE:exon41/91:c.6709G>A:p.Gly2237Ser:												2.3080	D(0.02)	B(0.40)	0.87,0.98	24.10	0.43				COSM418551,COSM7207008	0		0	0						LRP1B (inh=AR oe_syn=1.09 oe_mis=0.87 oe_lof=0.23)
chr2	141751554	141751554	G	A	0.1474	1348	0.0000	176		QUAL=166	LRP1B	intron	LRP1B:ENST00000389484:intron_variant:MODIFIER:exon16/90:c.2644+10C>T::	regulatory_region_variant:enhancer											1.0450			0.48,0.84	13.22						0		0	0						LRP1B (inh=AR oe_syn=1.09 oe_mis=0.87 oe_lof=0.23)
chr2	189856241	189856241	G	A	0.1128	413	0.0000	244		QUAL=160	COL3A1	missense	COL3A1:ENST00000304636:missense_variant:MODERATE:exon12/51:c.881G>A:p.Gly294Glu:PF01391,COL3A1:ENST00000317840:missense_variant:MODERATE:exon12/42:c.881G>A:p.Gly294Glu:PF01391		120180 [COL3A1 Ehlers-Danlos syndrome,vascular type,130050,Autosomal dominant/Polymicrogyria with or without vascular-type EDS,618343,Autosomal recessive];										9.1360	D(0.00),D(0.00)	D(1.00),D(1.00)	1.00,1.00	31.00	0.99				COSM74218	0		0	0						COL3A1 (inh=AD oe_syn=1.05 oe_mis=0.59 oe_lof=0.04)
chr2	189858183	189858183	C	T	0.1597	387	0.0000	74		QUAL=105	COL3A1	missense&splice_region	COL3A1:ENST00000304636:missense_variant&splice_region_variant:MODERATE:exon16/51:c.1147C>T:p.Pro383Ser:PF01391,COL3A1:ENST00000317840:missense_variant&splice_region_variant:MODERATE:exon16/42:c.1147C>T:p.Pro383Ser:		120180 [COL3A1 Ehlers-Danlos syndrome,vascular type,130050,Autosomal dominant/Polymicrogyria with or without vascular-type EDS,618343,Autosomal recessive];										1.3040	T(0.32),T(0.50)	B(0.03),B(0.01)	0.89,0.98	22.30	0.37	7.53>7.96		0.230/0.472		0		0	0						COL3A1 (inh=AD oe_syn=1.05 oe_mis=0.59 oe_lof=0.04)
chr2	212566773	212566773	G	A	0.1665	1709	0.0000	252		QUAL=230	ERBB4	missense	ERBB4:ENST00000342788:missense_variant:MODERATE:exon12/28:c.1408C>T:p.His470Tyr:PF01030,ERBB4:ENST00000402597:missense_variant:MODERATE:exon12/28:c.1408C>T:p.His470Tyr:PF01030,ERBB4:ENST00000436443:missense_variant:MODERATE:exon12/27:c.1408C>T:p.His470Tyr:PF01030		600543 [ERBB4 Amyotrophic lateral sclerosis 19,615515,Autosomal dominant];										4.2820	D(0.01),D(0.01),D(0.01)	P(0.78),P(0.57),P(0.67)	0.93,0.99	25.70	0.29				COSM6930066,COSM6930067	0		0	0						ERBB4 (inh=AD oe_syn=1.16 oe_mis=0.78 oe_lof=0.17)
chr3	38646214	38646214	G	A	0.1700	1302	0.0000	64		QUAL=98	SCN5A	splice_region&intron	SCN5A:ENST00000333535:splice_region_variant&intron_variant:LOW:exon11/27:c.1518+6C>T::,SCN5A:ENST00000413689:splice_region_variant&intron_variant:LOW:exon11/27:c.1518+6C>T::,SCN5A:ENST00000414099:splice_region_variant&intron_variant:LOW:exon10/25:c.1518+6C>T::,SCN5A:ENST00000423572:splice_region_variant&intron_variant:LOW:exon10/26:c.1518+6C>T::,SCN5A:ENST00000425664:splice_region_variant&intron_variant:LOW:exon11/26:c.1518+6C>T::,SCN5A:ENST00000443581:splice_region_variant&intron_variant:LOW:exon11/27:c.1518+6C>T::,SCN5A:ENST00000449557:splice_region_variant&intron_variant:LOW:exon10/25:c.1518+6C>T::,SCN5A:ENST00000450102:splice_region_variant&intron_variant:LOW:exon10/25:c.1518+6C>T::,SCN5A:ENST00000451551:splice_region_variant&intron_variant:LOW:exon11/26:c.1518+6C>T::,SCN5A:ENST00000455624:splice_region_variant&intron_variant:LOW:exon10/26:c.1518+6C>T::		600163 [SCN5A Atrial fibrillation,familial,10,614022,Autosomal dominant/Brugada syndrome 1,601144,Autosomal dominant/Cardiomyopathy,dilated,1E,601154,Autosomal dominant/Heart block,nonprogressive,113900,Autosomal dominant/Heart block,progressive,type IA,113900,Autosomal dominant/Long QT syndrome-3,603830,Autosomal dominant/Sick sinus syndrome 1,608567,Autosomal recessive/Sudden infant death syndrome,susceptibility to,272120,Autosomal recessive/Ventricular fibrillation,familial,1,603829];										2.1320			0.90,0.99	14.82		4.14>6.49		0.001/0.032	COSM5897464,COSM5897465,COSM5897466	1	Novartis	0	0						SCN5A (inh=AR+AD oe_syn=0.98 oe_mis=0.77 oe_lof=0.21)
chr3	105377996	105377996	G	A	0.1424	1296	0.0000	161		QUAL=165	CBLB	missense	CBLB:ENST00000264122:missense_variant:MODERATE:exon19/19:c.2767C>T:p.His923Tyr:,CBLB:ENST00000394027:missense_variant:MODERATE:exon18/18:c.2701C>T:p.His901Tyr:,CBLB:ENST00000407712:missense_variant:MODERATE:exon4/4:c.412C>T:p.His138Tyr:												3.9420	T(0.54),T(0.93),T(0.59)	B(0.00),B(0.00),B(0.00)	0.90,0.98	20.90	0.32					0		0	0						CBLB (inh=n/a oe_syn=1.03 oe_mis=0.83 oe_lof=0.14)
chr3	138374293	138374293	C	T	0.1579	2486	0.0000	219		QUAL=204	PIK3CB	missense	PIK3CB:ENST00000289153:missense_variant:MODERATE:exon22/22:c.3151G>A:p.Glu1051Lys:,PIK3CB:ENST00000477593:missense_variant:MODERATE:exon23/23:c.3151G>A:p.Glu1051Lys:,PIK3CB:ENST00000544716:missense_variant:MODERATE:exon15/15:c.1504G>A:p.Glu502Lys:												7.6530	D(0.03),D(0.03),T(0.48)	P(0.46),P(0.46),B(0.16)	0.99,1.00	31.00	0.57				COSM317875	1	Novartis	0	0						PIK3CB (inh=n/a oe_syn=0.91 oe_mis=0.62 oe_lof=0.13)
chr3	168807882	168807882	C	T	0.1590	1738	0.0000	260		QUAL=235	MECOM	missense	MECOM:ENST00000264674:missense_variant:MODERATE:exon15/17:c.2938G>A:p.Glu980Lys:,MECOM:ENST00000392736:missense_variant:MODERATE:exon14/16:c.2743G>A:p.Glu915Lys:,MECOM:ENST00000433243:missense_variant:MODERATE:exon15/17:c.2746G>A:p.Glu916Lys:,MECOM:ENST00000460814:missense_variant:MODERATE:exon12/15:c.2716G>A:p.Glu906Lys:,MECOM:ENST00000464456:missense_variant:MODERATE:exon13/15:c.2716G>A:p.Glu906Lys:,MECOM:ENST00000468789:missense_variant:MODERATE:exon14/16:c.2743G>A:p.Glu915Lys:,MECOM:ENST00000472280:missense_variant:MODERATE:exon14/16:c.2746G>A:p.Glu916Lys:,MECOM:ENST00000494292:missense_variant:MODERATE:exon14/16:c.3280G>A:p.Glu1094Lys:	regulatory_region_variant:enhancer	165215 [MECOM Radioulnar synostosis with amegakaryocytic thrombocytopenia 2,616738,Autosomal dominant],600049 [MECOM Myelodysplasia syndrome-1];										4.6230	T(0.29),T(0.30),T(0.31),T(0.30),T(0.30),T(0.30),T(0.31),T(0.31)	B(0.01),B(0.01),B(0.01),B(0.00),B(0.17),B(0.01),B(0.01),B(0.17)	0.95,0.99	20.90	0.19				COSM1693765,COSM1693766	0		0	0						MECOM (inh=AD oe_syn=1.10 oe_mis=0.81 oe_lof=0.04)
chr3	183210467	183210467	G	A	0.1480	1529	0.0000	102		QUAL=124	KLHL6	missense	KLHL6:ENST00000341319:missense_variant:MODERATE:exon6/7:c.1379C>T:p.Ser460Phe:PF01344	regulatory_region_variant:promoter_flanking_region											9.4770	D(0.00)	D(1.00)	0.99,0.99	31.00	0.91					0		0	0						KLHL6 (inh=n/a oe_syn=1.07 oe_mis=0.83 oe_lof=0.51)
chr3	190212686	190212686	G	A	0.1600	354	0.0000	195		QUAL=155		intergenic	::intergenic_variant:MODIFIER::::												0.4420			0.03,0.16	1.15						0		0	0						 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)
chr4	143045911	143045911	C	T	0.0906	935	0.0000	146		QUAL=89	INPP4B	missense&splice_region	INPP4B:ENST00000262992:missense_variant&splice_region_variant:MODERATE:exon17/24:c.1723G>A:p.Asp575Asn:,INPP4B:ENST00000308502:missense_variant&splice_region_variant:MODERATE:exon16/23:c.1723G>A:p.Asp575Asn:,INPP4B:ENST00000508116:missense_variant&splice_region_variant:MODERATE:exon18/25:c.1723G>A:p.Asp575Asn:,INPP4B:ENST00000509777:missense_variant&splice_region_variant:MODERATE:exon19/26:c.1723G>A:p.Asp575Asn:,INPP4B:ENST00000513000:missense_variant&splice_region_variant:MODERATE:exon20/27:c.1723G>A:p.Asp575Asn:												3.1000	D(0.03),D(0.03),D(0.03),D(0.03),D(0.03)	B(0.03),B(0.03),B(0.03),B(0.02),B(0.03)	0.94,0.98	24.40	0.09	9.45>9.46				0		0	0						INPP4B (inh=n/a oe_syn=1.00 oe_mis=0.84 oe_lof=0.22)
chr4	143045912	143045912	C	A	0.0921	929	0.0000	144		QUAL=117	INPP4B	missense&splice_region	INPP4B:ENST00000262992:missense_variant&splice_region_variant:MODERATE:exon17/24:c.1722G>T:p.Glu574Asp:,INPP4B:ENST00000308502:missense_variant&splice_region_variant:MODERATE:exon16/23:c.1722G>T:p.Glu574Asp:,INPP4B:ENST00000508116:missense_variant&splice_region_variant:MODERATE:exon18/25:c.1722G>T:p.Glu574Asp:,INPP4B:ENST00000509777:missense_variant&splice_region_variant:MODERATE:exon19/26:c.1722G>T:p.Glu574Asp:,INPP4B:ENST00000513000:missense_variant&splice_region_variant:MODERATE:exon20/27:c.1722G>T:p.Glu574Asp:												0.0820	T(0.44),T(0.44),T(0.44),T(0.44),T(0.44)	B(0.00),B(0.00),B(0.00),B(0.00),B(0.00)	0.29,0.94	16.93	0.02	9.45>10.86		0.000/0.002		0		0	0						INPP4B (inh=n/a oe_syn=1.00 oe_mis=0.84 oe_lof=0.22)
chr5	37010243	37010243	A	T	0.1261	580	0.0000	226		QUAL=158	NIPBL	synonymous	NIPBL:ENST00000282516:synonymous_variant:LOW:exon21/47:c.4476A>T:p.Ala1492=:,NIPBL:ENST00000448238:synonymous_variant:LOW:exon21/46:c.4476A>T:p.Ala1492=:		608667 [NIPBL Cornelia de Lange syndrome 1,122470,Autosomal dominant];										-0.2980			0.25,0.97	10.69						0		0	0						NIPBL (inh=AD oe_syn=0.98 oe_mis=0.57 oe_lof=0.01)
chr5	180041065	180041065	C	T	0.1403	1285	0.0000	83		QUAL=77	FLT4	splice_region&intron	FLT4:ENST00000261937:splice_region_variant&intron_variant:LOW:exon24/29:c.3331+3G>A::,FLT4:ENST00000393347:splice_region_variant&intron_variant:LOW:exon24/29:c.3331+3G>A::,FLT4:ENST00000502649:splice_region_variant&intron_variant:LOW:exon24/29:c.3331+3G>A::		136352 [FLT4 Hemangioma,capillary infantile,somatic,602089/Lymphatic malformation 1,153100,Autosomal dominant];				rs1258606058		0.0001	0,.			1.0770			0.71,0.97	14.22		8.73>10.24		0.000/0.000		0		0	0						FLT4 (inh=AD oe_syn=1.11 oe_mis=0.71 oe_lof=0.07)
chr6	6269291	6269291	C	T	0.0109	963	0.0000	238	freq-tum	QUAL=56	F13A1	intron	F13A1:ENST00000264870:intron_variant:MODIFIER:exon3/14:c.320-2249G>A::		134570 [F13A1 Factor XIIIA deficiency,613225,Autosomal recessive/Myocardial infarction,protection against,608446/Venous thrombosis,protection against,188050,Autosomal dominant];										-0.4160			0.01,0.10	0.12						0		0	0						F13A1 (inh=AR oe_syn=1.05 oe_mis=0.85 oe_lof=0.48)
chr6	74228684	74228684	C	T	0.1748	1574	0.0069	149		QUAL=139	EEF1A1	missense	EEF1A1:ENST00000309268:missense_variant:MODERATE:exon4/8:c.592G>A:p.Gly198Ser:PF00009,EEF1A1:ENST00000316292:missense_variant:MODERATE:exon3/7:c.592G>A:p.Gly198Ser:PF00009,EEF1A1:ENST00000331523:missense_variant:MODERATE:exon4/8:c.592G>A:p.Gly198Ser:PF00009	regulatory_region_variant:promoter,TF_binding_site_variant											7.4450	D(0.01),D(0.01),D(0.01)	P(0.82),P(0.82),P(0.82)	0.97,0.98	28.10	0.69					0		0	0						EEF1A1 (inh=n/a oe_syn=1.70 oe_mis=0.35 oe_lof=0.06)
chr6	117665238	117665238	C	T	0.2036	789	0.0000	171		QUAL=207	ROS1	synonymous	ROS1:ENST00000368507:synonymous_variant:LOW:exon28/44:c.4491G>A:p.Leu1497=:,ROS1:ENST00000368508:synonymous_variant:LOW:exon27/43:c.4509G>A:p.Leu1503=:												1.0600			0.04,0.22	3.85					COSM6930473,COSM6930474	0		0	0						ROS1 (inh=n/a oe_syn=1.11 oe_mis=1.03 oe_lof=0.93)
chr6	117706984	117706984	C	T	0.1845	1132	0.0000	173		QUAL=193	ROS1	synonymous	ROS1:ENST00000368507:synonymous_variant:LOW:exon16/44:c.2151G>A:p.Thr717=:,ROS1:ENST00000368508:synonymous_variant:LOW:exon15/43:c.2166G>A:p.Thr722=:						rs55944128	0.0018	0.0034	0,.	0.0115,0.0003,0.0000,0.0001,0.0000	0.0000,0.0125	-1.0820			0.02,0.19	6.05						2	Novartis	0	1						ROS1 (inh=n/a oe_syn=1.11 oe_mis=1.03 oe_lof=0.93)
chr6	152420046	152420046	C	T	0.2294	1589	0.0000	103		QUAL=160	ESR1	missense,intron	ESR1:ENST00000206249:missense_variant:MODERATE:exon8/8:c.1733C>T:p.Ser578Phe:PF12743,ESR1:ENST00000338799:missense_variant:MODERATE:exon9/9:c.1733C>T:p.Ser578Phe:PF12743,ESR1:ENST00000406599:missense_variant:MODERATE:exon4/4:c.950C>T:p.Ser317Phe:PF12743,ESR1:ENST00000427531:intron_variant:MODIFIER:exon6/6:c.851-26355C>T::,ESR1:ENST00000440973:missense_variant:MODERATE:exon10/10:c.1733C>T:p.Ser578Phe:PF12743,ESR1:ENST00000443427:missense_variant:MODERATE:exon9/9:c.1733C>T:p.Ser578Phe:PF12743,ESR1:ENST00000456483:missense_variant:MODERATE:exon8/8:c.1397C>T:p.Ser466Phe:PF12743	regulatory_region_variant:promoter_flanking_region	133430 [ESR1 Atherosclerosis,susceptibility to/Breast cancer,somatic,114480/Estrogen resistance,615363,Autosomal recessive/HDL response to hormone replacement,augmented/Migraine,susceptibility to,157300,Autosomal dominant/Myocardial infarction,susceptibility to,608446];				rs781018265		0.0001		0.0000,0.0000,0.0000,0.0000,0.0001		3.9780	D(0.00),D(0.00),D(0.00), ,D(0.00),D(0.00),D(0.00)	P(0.88),P(0.88),D(0.93), ,P(0.88),P(0.88),P(0.81)	0.91,0.94	27.50	0.54				COSM224935	0		0	0						ESR1 (inh=AR oe_syn=1.09 oe_mis=0.73 oe_lof=0.04)
chr7	14010136	14010136	G	A	0.1081	149	0.0000	108		QUAL=95	ETV1	intron	ETV1:ENST00000242066:intron_variant:MODIFIER:exon5/12:c.181+16127C>T::,ETV1:ENST00000343495:intron_variant:MODIFIER:exon5/12:c.181+16127C>T::,ETV1:ENST00000399357:intron_variant:MODIFIER:exon2/8:c.115+6916C>T::,ETV1:ENST00000403527:intron_variant:MODIFIER:exon2/9:c.115+6916C>T::,ETV1:ENST00000403685:intron_variant:MODIFIER:exon4/11:c.181+16127C>T::,ETV1:ENST00000405192:intron_variant:MODIFIER:exon5/11:c.235+6916C>T::,ETV1:ENST00000405218:intron_variant:MODIFIER:exon5/12:c.235+6916C>T::,ETV1:ENST00000405358:intron_variant:MODIFIER:exon4/11:c.277+6916C>T::,ETV1:ENST00000420159:intron_variant:MODIFIER:exon1/8:c.61+15605C>T::,ETV1:ENST00000430479:intron_variant:MODIFIER:exon6/13:c.235+6916C>T::												-0.9980			0.00,0.09	0.25						0		0	0						ETV1 (inh=AD oe_syn=1.28 oe_mis=0.84 oe_lof=0.16)
chr7	98574313	98574313	G	A	0.1674	2011	0.0000	139		QUAL=151	TRRAP	missense	TRRAP:ENST00000355540:missense_variant:MODERATE:exon53/71:c.8092G>A:p.Glu2698Lys:,TRRAP:ENST00000359863:missense_variant:MODERATE:exon54/72:c.8146G>A:p.Glu2716Lys:,TRRAP:ENST00000446306:missense_variant:MODERATE:exon52/70:c.8092G>A:p.Glu2698Lys:												9.5560	T(0.15),T(0.15),T(0.13)	B(0.05),B(0.02),B(0.06)	0.99,1.00	23.80	0.26					0		0	0						TRRAP (inh=n/a oe_syn=1.10 oe_mis=0.51 oe_lof=0.03)
chr7	106508094	106508094	G	A	0.1747	944	0.0000	76		QUAL=101	PIK3CG	missense	PIK3CG:ENST00000359195:missense_variant:MODERATE:exon2/11:c.88G>A:p.Ala30Thr:,PIK3CG:ENST00000440650:missense_variant:MODERATE:exon2/11:c.88G>A:p.Ala30Thr:,PIK3CG:ENST00000496166:missense_variant:MODERATE:exon2/11:c.88G>A:p.Ala30Thr:						rs1212203463		0.0001		0.0000,0.0000,0.0000,0.0001,0.0000		1.5440	T(0.26),T(0.26),T(0.26)	B(0.00),B(0.00),B(0.00)	0.36,0.29	13.44	0.17					0		0	0						PIK3CG (inh=n/a oe_syn=1.00 oe_mis=0.78 oe_lof=0.40)
chr7	140453136	140453136	A	T	0.1656	2239	0.0000	367		QUAL=308	BRAF	missense	BRAF:ENST00000288602:missense_variant:MODERATE:exon15/18:c.1799T>A:p.Val600Glu:PF07714		164757 [BRAF Adenocarcinoma of lung,somatic,211980/Cardiofaciocutaneous syndrome,115150,Autosomal dominant/Colorectal cancer,somatic/LEOPARD syndrome 3,613707,Autosomal dominant/Melanoma,malignant,somatic/Nonsmall cell lung cancer,somatic/Noonan syndrome 7,613706,Autosomal dominant];	13961 [pathogenic DISEASE=Cystic epithelial invagination containing papillae lined by columnar epithelium,Neoplasm,Papillary thyroid carcinoma,Multiple myeloma,Brainstem glioma,Cutaneous melanoma,Lung adenocarcinoma,Non-small cell lung cancer,Neoplasm of brain,Neoplasm of the colon,Gastrointestinal stroma tumor,Neoplasm of the large intestine,Squamous cell carcinoma of the head and neck,Papillary renal cell carcinoma, sporadic,Malignant melanoma of skin,Glioblastoma,Ovarian Neoplasms,Lung cancer,Carcinoma of colon,Germ cell tumor, nonseminomatous,Cardio-facio-cutaneous syndrome,Astrocytoma, low-grade, somatic,not provided];			rs113488022						9.2010	D(0.00)	D(0.96)	0.99,0.99	30.00	0.93				COSM18443,COSM476,COSM6137	97	ALM_Schleimhautmelanom,ARO-16,Novartis,PATHO_Somatic,Roecken_CheckpointInhibitor,SomaticAndTreatment,TEST_cfDNA_ThruPLEX_Tag-seq	3	3			[import GPD] Christopher Schroeder 2013-05-07 09:14:08 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/21663470?dopt=Abstract&holding=npg -doi: 10.1056/NEJMoa1014209 BRAF mutations in hairy-cell leukemia.  [import GPD] Christopher Schroeder 2013-05-07 09:14:45 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/22210875?dopt=Abstract&holding=npg -doi: 10.1182/blood-2011-09-379339 Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.  [import GPD] Christopher Schroeder 2013-05-02 17:26:11 -type: lit / druggable -link: http://www.nejm.org/doi/full/10.1056/NEJMc1215697?query=TOC -drugs: vemurafenib BRAF V600E Inhibition in Anaplastic Thyroid Cancer  [import GPD] Christopher Schroeder 2013-05-07 18:21:28 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/22395615?dopt=Abstract&holding=npg -doi: 10.1038/ncomms1727 Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.  [import GPD] Christopher Schroeder 2013-05-15 11:43:10 -type: lit / preclinical study -link: http://www.nature.com/nature/journal/v483/n7387/full/nature10868.html -doi: 10.1038/nature10868 -drugs: vemurafenib, cetuximab, gefitinib, panitumumab Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.  => Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8–10% of all colon cancers2, 3, 5), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.  [import GPD] Christopher Schroeder 2013-05-03 17:12:18 -type: lit / druggable -link: http://www.nejm.org/doi/full/10.1056/NEJMoa1103782 -drugs: vemurafenib Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation  [import GPD] Christopher Schroeder 2013-05-28 15:50:19 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/20818844 -doi: 10.1056/NEJMoa1002011 -drugs: vemurafenib Inhibition of mutated, activated BRAF in metastatic melanoma. => Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.  [import GPD] Christopher Schroeder 2013-06-05 15:32:18 -type: lit / druggable -link: http://jco.ascopubs.org/content/early/2013/06/03/JCO.2012.45.7739?papetoc -doi: 10.1200/JCO.2012.45.7739 -drugs: vemurafenib Rapid Response to Vemurafenib in a Heavily Pretreated Patient With Hairy Cell Leukemia and a BRAF Mutation  [import GPD] Christopher Schroeder 2013-09-04 10:29:28 -type: lit / preclinical study -link: http://www.ncbi.nlm.nih.gov/pubmed/18676837 -doi: 10.1158/0008-5472.CAN-08-1430 -drugs: selumetinib, Trametinib Tumors harboring BRAF V600E mutations lack this negative feedback loop and are sensitive to MEK inhibitors.  [import GPD] Christopher Schroeder 2013-12-22 15:16:45 -type: lit / clinical trial -link: http://jco.ascopubs.org/content/31/35/e448?cmpid=jco_etoc_10December2013 -doi: 10.1200/JCO.2013.50.4118 -drugs: dabrafenib, Trametinib BRAF Inhibitor–Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition => First, caution must be exercised when using BRAFis in patients or populations that might harbor RAS-mutated cells, be they in skin, bowel, or other sites.  [import GPD] Christopher Schroeder 2013-06-05 15:27:37 -type: case report -link: http://jco.ascopubs.org/content/early/2013/06/03/JCO.2012.47.6143?papetoc -doi: 10.1200/JCO.2012.47.6143 -drugs: vemurafenib, radiation Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma. Radiosensitizing effect of vemurafenib ("should probably not be combined with radiation").			BRAF (inh=AR+AD oe_syn=1.01 oe_mis=0.48 oe_lof=0.10)
chr7	151947956	151947956	G	A	0.1809	1239	0.0000	276		QUAL=238	KMT2C	missense	KMT2C:ENST00000262189:missense_variant:MODERATE:exon12/59:c.1717C>T:p.Pro573Ser:,KMT2C:ENST00000355193:missense_variant:MODERATE:exon12/60:c.1717C>T:p.Pro573Ser:		606833 [KMT2C Kleefstra syndrome 2,617768,Autosomal dominant];										1.0640	T(0.10),T(0.09)	B(0.25),B(0.44)	0.76,0.98	22.80	0.26				COSM6927260,COSM6927261	0		0	0						KMT2C (inh=AD oe_syn=1.00 oe_mis=0.86 oe_lof=0.08)
chr8	38297867	38297867	G	A	0.1489	551	0.0000	113		QUAL=128	FGFR1	intron,synonymous	FGFR1:ENST00000326324:intron_variant:MODIFIER:exon2/16:c.92-11914C>T::,FGFR1:ENST00000335922:synonymous_variant:LOW:exon3/19:c.24C>T:p.Phe8=:,FGFR1:ENST00000341462:intron_variant:MODIFIER:exon2/17:c.92-10401C>T::,FGFR1:ENST00000356207:intron_variant:MODIFIER:exon2/16:c.92-11914C>T::,FGFR1:ENST00000397091:intron_variant:MODIFIER:exon2/17:c.92-10401C>T::,FGFR1:ENST00000397103:intron_variant:MODIFIER:exon1/15:c.92-11914C>T::,FGFR1:ENST00000397108:intron_variant:MODIFIER:exon3/18:c.92-10401C>T::,FGFR1:ENST00000397113:intron_variant:MODIFIER:exon2/17:c.92-10401C>T::,FGFR1:ENST00000425967:intron_variant:MODIFIER:exon3/18:c.191-10401C>T::,FGFR1:ENST00000447712:intron_variant:MODIFIER:exon2/17:c.92-10401C>T::,FGFR1:ENST00000532791:intron_variant:MODIFIER:exon2/17:c.92-10401C>T::		136350 [FGFR1 Encephalocraniocutaneous lipomatosis,613001,Somatic mosaicism/Hartsfield syndrome,615465,Autosomal dominant/Hypogonadotropic hypogonadism 2 with or without anosmia,147950,Autosomal dominant/Jackson-Weiss syndrome,123150,Autosomal dominant/Osteoglophonic dysplasia,166250,Autosomal dominant/Pfeiffer syndrome,101600,Autosomal dominant/Trigonocephaly 1,190440,Autosomal dominant];				rs778168231		0.0001	0,.	0.0000,0.0000,0.0002,0.0001,0.0002		-2.2040			0.00,0.11	0.08					COSM2960592	1	Novartis	0	0						FGFR1 (inh=AD oe_syn=1.16 oe_mis=0.70 oe_lof=0.10)
chr8	86485291	86485291	C	T	0.1669	1834	0.0000	158		QUAL=162		intergenic	::intergenic_variant:MODIFIER::::						rs940002226						-0.3260			0.03,0.13	1.82						1	Novartis	0	0						 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)
chr9	139393544	139393544	C	T	0.1843	841	0.0000	38		QUAL=88	NOTCH1	intron	NOTCH1:ENST00000277541:intron_variant:MODIFIER:exon32/33:c.6082+20G>A::		190198 [NOTCH1 Adams-Oliver syndrome 5,616028,Autosomal dominant/Aortic valve disease 1,109730,Autosomal dominant];										-1.3370			0.06,0.23	2.36						0		0	0						NOTCH1 (inh=AD oe_syn=1.14 oe_mis=0.74 oe_lof=0.04)
chr9	139404351	139404351	G	A	0.2367	513	0.0000	46		QUAL=104	NOTCH1	missense	NOTCH1:ENST00000277541:missense_variant:MODERATE:exon18/34:c.2803C>T:p.Pro935Ser:PF00008		190198 [NOTCH1 Adams-Oliver syndrome 5,616028,Autosomal dominant/Aortic valve disease 1,109730,Autosomal dominant];				rs1230159701						2.9870	D(0.00)	P(0.73)	0.93,0.97	24.70	0.38					0		0	0						NOTCH1 (inh=AD oe_syn=1.14 oe_mis=0.74 oe_lof=0.04)
chr10	43612102	43612102	G	A	0.1549	688	0.0000	98		QUAL=121	RET	missense	RET:ENST00000340058:missense_variant:MODERATE:exon12/19:c.2207G>A:p.Gly736Glu:PF07714,RET:ENST00000355710:missense_variant:MODERATE:exon12/20:c.2207G>A:p.Gly736Glu:PF07714		164761 [RET Central hypoventilation syndrome,congenital,209880,Autosomal dominant/Hirschsprung disease,protection against,142623,Autosomal dominant/Hirschsprung disease,susceptibility to,1,142623,Autosomal dominant/Medullary thyroid carcinoma,155240,Autosomal dominant/Multiple endocrine neoplasia IIA,171400,Autosomal dominant/Multiple endocrine neoplasia IIB,162300,Autosomal dominant/Pheochromocytoma,171300,Autosomal dominant];										9.8730	D(0.00),D(0.00)	D(1.00),D(1.00)	0.99,1.00	32.00	0.97				COSM6962596,COSM6962597	0		0	0						RET (inh=AR+AD oe_syn=1.01 oe_mis=0.88 oe_lof=0.04)
chr10	70406352	70406352	C	T	0.1757	1662	0.0000	201		QUAL=199	TET1	missense	TET1:ENST00000373644:missense_variant:MODERATE:exon4/12:c.3866C>T:p.Thr1289Met:						rs575341146		0.0001	0,.	0.0001,0.0001,0.0001,0.0001,0.0002		-0.0870	T(0.10)	B(0.23)	0.09,0.29	15.31	0.05				COSM4015294	0		0	1						TET1 (inh=n/a oe_syn=0.98 oe_mis=0.86 oe_lof=0.09)
chr11	17741387	17741387	C	T	0.1995	1261	0.0000	71		QUAL=122	MYOD1	missense	MYOD1:ENST00000250003:missense_variant:MODERATE:exon1/3:c.58C>T:p.Leu20Phe:	regulatory_region_variant:promoter											4.1450	D(0.05)	D(0.94)	0.92,0.96	28.80	0.39					0		0	0						MYOD1 (inh=n/a oe_syn=1.01 oe_mis=1.07 oe_lof=0.34)
chr11	59211127	59211127	G	A	0.1596	2352	0.0000	109		QUAL=130	OR5A1	synonymous	OR5A1:ENST00000302030:synonymous_variant:LOW:exon1/1:c.486G>A:p.Gln162=:PF13853												-0.7860			0.25,0.97	6.61						0		0	0						OR5A1 (inh=n/a oe_syn=1.23 oe_mis=1.14 oe_lof=0.95)
chr11	62098324	62098324	C	T	0.1714	141	0.0000	21	off-target	QUAL=60	NPM1P35	upstream_gene	NPM1P35:ENST00000533043:upstream_gene_variant:MODIFIER::::	regulatory_region_variant:promoter_flanking_region											0.6560			0.04,0.12	5.08						2	SomaticAndTreatment	0	0						NPM1P35 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)
chr11	70279245	70279245	C	T	0.1364	421	0.0000	39		QUAL=79	CTTN	synonymous	CTTN:ENST00000301843:synonymous_variant:LOW:exon16/18:c.1305C>T:p.Gly435=:,CTTN:ENST00000346329:synonymous_variant:LOW:exon15/17:c.1194C>T:p.Gly398=:,CTTN:ENST00000376561:synonymous_variant:LOW:exon15/19:c.1194C>T:p.Gly398=:,CTTN:ENST00000538675:synonymous_variant:LOW:exon7/10:c.357C>T:p.Gly119=:												-0.3360			0.07,0.19	0.65						0		0	0						CTTN (inh=n/a oe_syn=1.03 oe_mis=0.87 oe_lof=0.26)
chr11	93528219	93528219	C	T	0.1467	1032	0.0000	201		QUAL=188	MED17	synonymous	MED17:ENST00000251871:synonymous_variant:LOW:exon6/12:c.1005C>T:p.Pro335=:PF10156		603810 [MED17 Microcephaly,postnatal progressive,with seizures and brain atrophy,613668,Autosomal recessive];										-0.7080			0.18,0.94	16.71						0		0	0						MED17 (inh=AR oe_syn=0.90 oe_mis=0.85 oe_lof=0.54)
chr11	133495538	133495538	A	C	0.1830	987	0.0000	161		QUAL=178		intergenic	::intergenic_variant:MODIFIER::::					L2c (LINE/L2)							-0.2920			0.02,0.11	2.26						0		0	0						 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)
chr12	460082	460082	G	A	0.1667	18	0.0000	16	depth-tum;depth-nor;off-target	QUAL=42	KDM5A	intron	KDM5A:ENST00000382815:intron_variant:MODIFIER:exon9/27:c.1150-137C>T::,KDM5A:ENST00000399788:intron_variant:MODIFIER:exon9/27:c.1150-137C>T::						rs115835122	0.0020	0.0015	0,.			-0.9010			0.02,0.05	0.01						0		0	0						KDM5A (inh=n/a oe_syn=1.15 oe_mis=0.78 oe_lof=0.09)
chr12	12036213	12036213	T	C	0.6524	178	0.1607	67	freq-nor	QUAL=42	ETV6	intron	ETV6:ENST00000396373:intron_variant:MODIFIER:exon5/7:c.1010-1166T>C::	regulatory_region_variant:promoter_flanking_region	600618 [ETV6 Leukemia,acute myeloid,somatic,601626/Thrombocytopenia 5,616216,Autosomal dominant];			AluSz (SINE/Alu)	rs2723820		0.1040	451,.			-1.6490			0.00,0.08	0.79						1	Novartis	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					ETV6 (inh=AD oe_syn=1.17 oe_mis=0.70 oe_lof=0.09)
chr12	21030706	21030706	G	T	0.1510	252	0.0000	106		QUAL=114	SLCO1B3,LST3,SLCO1B7	missense&splice_region,intron	SLCO1B3:ENST00000261196:missense_variant&splice_region_variant:MODERATE:exon9/15:c.971G>T:p.Gly324Val:PF03137,LST3:ENST00000381541:intron_variant:MODIFIER:exon3/13:c.359+19201G>T::,SLCO1B3:ENST00000381545:missense_variant&splice_region_variant:MODERATE:exon10/16:c.971G>T:p.Gly324Val:PF03137,LST3:ENST00000540229:missense_variant&splice_region_variant:MODERATE:exon8/16:c.971G>T:p.Gly324Val:PF03137,SLCO1B3:ENST00000553473:missense_variant&splice_region_variant:MODERATE:exon8/16:c.971G>T:p.Gly324Val:PF03137,SLCO1B7:ENST00000554957:intron_variant:MODIFIER:exon3/13:c.359+19201G>T::		605495 [SLCO1B3 Hyperbilirubinemia,Rotor type,digenic,237450,Digenic recessive];										0.8020	D(0.00), ,D(0.00),D(0.01),D(0.01), 	P(0.74), ,P(0.74),P(0.88),P(0.88), 	0.74,0.93	22.50	0.16	9.01>6.22		0.927/0.640		0		0	0						SLCO1B3 (inh=AR oe_syn=1.05 oe_mis=1.18 oe_lof=1.19), SLCO1B7 (inh=n/a oe_syn=1.21 oe_mis=1.16 oe_lof=1.34), SLCO1B7 (inh=n/a oe_syn=1.21 oe_mis=1.16 oe_lof=1.34)
chr12	33031024	33031024	C	T	0.1709	478	0.0000	34		QUAL=78	PKP2	missense	PKP2:ENST00000070846:missense_variant:MODERATE:exon3/14:c.790G>A:p.Ala264Thr:,PKP2:ENST00000340811:missense_variant:MODERATE:exon3/13:c.790G>A:p.Ala264Thr:		602861 [PKP2 Arrhythmogenic right ventricular dysplasia 9,609040,Autosomal dominant];										-0.7350	T(0.31),T(0.34)	B(0.00),B(0.00)	0.02,0.11	0.01	0.18				COSM4434145	0		0	0						PKP2 (inh=AD oe_syn=0.97 oe_mis=1.00 oe_lof=0.78)
chr12	96106972	96106972	C	T	0.1597	1408	0.0000	175		QUAL=176	NTN4	intron	NTN4:ENST00000343702:intron_variant:MODIFIER:exon4/9:c.991+18G>A::,NTN4:ENST00000344911:intron_variant:MODIFIER:exon5/10:c.880+18G>A::,NTN4:ENST00000538383:intron_variant:MODIFIER:exon4/9:c.880+18G>A::,NTN4:ENST00000553059:intron_variant:MODIFIER:exon4/8:c.991+18G>A::						rs538571907	0.0002	0.0001	0,.	0.0000,0.0000,0.0000,0.0001,0.0002		-0.7730			0.00,0.12	0.41						0		0	0						NTN4 (inh=n/a oe_syn=0.91 oe_mis=0.74 oe_lof=0.15)
chr12	106895076	106895076	C	T	0.1532	1042	0.0000	133		QUAL=122	POLR3B,RP11-144F15.1	intron	POLR3B:ENST00000228347:intron_variant:MODIFIER:exon25/27:c.2985-25C>T::,POLR3B:ENST00000539066:intron_variant:MODIFIER:exon25/27:c.2811-25C>T::,RP11-144F15.1:ENST00000551505:intron_variant:MODIFIER:exon1/2:c.210-1116G>A::		614366 [POLR3B Leukodystrophy,hypomyelinating,8,with or without oligodontia and/or hypogonadotropic hypogonadism,614381,Autosomal recessive];										0.3290			0.07,0.23	2.28						0		0	0						POLR3B (inh=AR oe_syn=0.92 oe_mis=0.63 oe_lof=0.63), RP11-144F15.1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)
chr12	133201370	133201370	G	A	0.2000	918	0.0000	74		QUAL=125	POLE	synonymous	POLE:ENST00000320574:synonymous_variant:LOW:exon49/49:c.6774C>T:p.Phe2258=:,POLE:ENST00000535270:synonymous_variant:LOW:exon48/48:c.6693C>T:p.Phe2231=:	regulatory_region_variant:promoter_flanking_region	174762 [POLE Colorectal cancer,susceptibility to,12,615083,Autosomal dominant/FILS syndrome,615139,Autosomal recessive/IMAGE-I syndrome,618336,Autosomal recessive];				rs1209347208		0.0001		0.0000,0.0000,0.0001,0.0000,0.0000		4.2640			0.95,0.99	17.35						0		0	0						POLE (inh=AR+AD oe_syn=1.04 oe_mis=0.91 oe_lof=0.51)
chr13	32913257	32913257	C	T	0.2025	817	0.0000	222		QUAL=245	BRCA2	missense	BRCA2:ENST00000380152:missense_variant:MODERATE:exon11/27:c.4765C>T:p.Pro1589Ser:,BRCA2:ENST00000544455:missense_variant:MODERATE:exon11/28:c.4765C>T:p.Pro1589Ser:		600185 [BRCA2 Breast cancer,male,susceptibility to,114480,Autosomal dominant,Somatic mutation/Breast-ovarian cancer,familial,2,612555,Autosomal dominant/Fanconi anemia,complementation group D1,605724,Autosomal recessive/Glioblastoma 3,613029,Autosomal recessive/Medulloblastoma,155255,Autosomal recessive,Autosomal dominant/Pancreatic cancer 2,613347/Prostate cancer,176807,Autosomal dominant,Somatic mutation/Wilms tumor,194070,Autosomal dominant,Somatic mutation];										-0.2470	T(0.19),T(0.19)	B(0.17),B(0.17)	0.09,0.25	11.26	0.24				COSM6931433,COSM6931434	0		0	0						BRCA2 (inh=AR+AD oe_syn=0.96 oe_mis=1.07 oe_lof=0.50)
chr14	23899862	23899862	C	T	0.1941	652	0.0000	55		QUAL=102	MYH7	synonymous	MYH7:ENST00000355349:synonymous_variant:LOW:exon11/40:c.906G>A:p.Leu302=:PF00063		160760 [MYH7 Cardiomyopathy,dilated,1S,613426,Autosomal dominant/Cardiomyopathy,hypertrophic,1,192600,Autosomal dominant/Laing distal myopathy,160500,Autosomal dominant/Left ventricular noncompaction 5,613426,Autosomal dominant/Myopathy,myosin storage,autosomal dominant,608358,Autosomal dominant/Myopathy,myosin storage,autosomal recessive,255160,Autosomal recessive/Scapuloperoneal syndrome,myopathic type,181430,Autosomal dominant];										-0.1540			0.21,0.97	11.57						0		0	0						MYH7 (inh=AR+AD oe_syn=1.23 oe_mis=0.67 oe_lof=0.45)
chr15	63950920	63950920	G	A	0.1925	840	0.0000	113		QUAL=147	HERC1	splice_region&intron	HERC1:ENST00000443617:splice_region_variant&intron_variant:LOW:exon47/77:c.9425-3C>T::		605109 [HERC1 Macrocephaly,dysmorphic facies,and psychomotor retardation,617011,Autosomal recessive];										1.6970			0.94,0.97	14.48		6.18>6.32		0.005/0.272		0		0	0						HERC1 (inh=AR oe_syn=1.00 oe_mis=0.70 oe_lof=0.17)
chr15	66729162	66729162	C	T	0.1833	2499	0.0000	147		QUAL=190	MAP2K1	missense	MAP2K1:ENST00000307102:missense_variant:MODERATE:exon3/11:c.370C>T:p.Pro124Ser:PF00069		176872 [MAP2K1 Cardiofaciocutaneous syndrome 3,615279];	375981 [pathogenic DISEASE=Transitional cell carcinoma of the bladder,Cutaneous melanoma,Neoplasm of the large intestine,Malignant melanoma of skin,Malignant neoplasm of body of uterus,not provided];			rs1057519732						7.7080	T(0.08)	D(0.99)	0.99,0.99	24.90	0.86				COSM235614	1	Novartis	0	0						MAP2K1 (inh=AD oe_syn=1.08 oe_mis=0.39 oe_lof=0.14)
chr15	66729163	66729163	C	T	0.1835	2516	0.0000	148		QUAL=192	MAP2K1	missense	MAP2K1:ENST00000307102:missense_variant:MODERATE:exon3/11:c.371C>T:p.Pro124Leu:PF00069		176872 [MAP2K1 Cardiofaciocutaneous syndrome 3,615279];	40744 [pathogenic/likely pathogenic DISEASE=Transitional cell carcinoma of the bladder,Cutaneous melanoma,Neoplasm of the large intestine,Malignant melanoma of skin,Malignant neoplasm of body of uterus,Cardio-facio-cutaneous syndrome,not provided];	CM071852 [CLASS=DM MUT=ALT PHEN="Cardio-facio-cutaneous syndrome" GENE=MAP2K1];		rs397516792						7.7080	D(0.00)	D(1.00)	0.99,0.99	29.00	0.91				COSM1167912,COSM1315861,COSM6986263	6	Novartis,SomaticAndTreatment	0	0						MAP2K1 (inh=AD oe_syn=1.08 oe_mis=0.39 oe_lof=0.14)
chr15	67358694	67358694	C	T	0.0833	108	0.0000	31		QUAL=59	SMAD3	missense	SMAD3:ENST00000327367:missense_variant:MODERATE:exon1/9:c.202C>T:p.Pro68Ser:PF03165	regulatory_region_variant:promoter,regulatory_region_variant:CTCF_binding_site	603109 [SMAD3 Loeys-Dietz syndrome 3,613795,Autosomal dominant];				rs1307168753		0.0001		0.0000,0.0000,0.0000,0.0000,0.0001		7.3360	T(0.08)	P(0.61)	0.93,0.97	25.60	0.68					0		0	0						SMAD3 (inh=AD oe_syn=1.09 oe_mis=0.39 oe_lof=0.17)
chr16	14016080	14016080	A	C	0.1972	366	0.0000	99		QUAL=135	ERCC4	intron	ERCC4:ENST00000311895:intron_variant:MODIFIER:exon2/10:c.388+12A>C::,ERCC4:ENST00000575156:intron_variant:MODIFIER:exon2/5:c.388+12A>C::		133520 [ERCC4 Fanconi anemia,complementation group Q,615272,Autosomal recessive/XFE progeroid syndrome,610965,Autosomal recessive/Xeroderma pigmentosum,group F,278760,Autosomal recessive/Xeroderma pigmentosum,type F/Cockayne syndrome,278760,Autosomal recessive];										0.7750			0.35,0.91	11.94						0		0	0						ERCC4 (inh=AR oe_syn=1.13 oe_mis=1.08 oe_lof=0.64)
chr16	14041833	14041833	C	T	0.1806	2665	0.0000	189		QUAL=216	ERCC4	missense	ERCC4:ENST00000311895:missense_variant:MODERATE:exon11/11:c.2380C>T:p.His794Tyr:PF02732		133520 [ERCC4 Fanconi anemia,complementation group Q,615272,Autosomal recessive/XFE progeroid syndrome,610965,Autosomal recessive/Xeroderma pigmentosum,group F,278760,Autosomal recessive/Xeroderma pigmentosum,type F/Cockayne syndrome,278760,Autosomal recessive];				rs757223070		0.0001		0.0000,0.0001,0.0000,0.0001,0.0000		7.2720	D(0.00)	D(0.99)	0.99,1.00	29.20	0.46					1	Novartis	0	0						ERCC4 (inh=AR oe_syn=1.13 oe_mis=1.08 oe_lof=0.64)
chr16	31196694	31196694	C	T	0.1805	1087	0.0000	178		QUAL=192	FUS	intron	FUS:ENST00000254108:intron_variant:MODIFIER:exon6/14:c.764+194C>T::,FUS:ENST00000380244:intron_variant:MODIFIER:exon6/14:c.761+194C>T::,FUS:ENST00000568685:intron_variant:MODIFIER:exon6/14:c.764+194C>T::		137070 [FUS Amyotrophic lateral sclerosis 6,with or without frontotemporal dementia,608030/Essential tremor,hereditary,4,614782,Autosomal dominant];										-0.0160			0.08,0.41	12.57						0		0	0						FUS (inh=AR+AD oe_syn=1.24 oe_mis=0.65 oe_lof=0.10)
chr17	9423073	9423073	-	C	0.9091	13	0.0000	2	depth-tum;depth-nor;off-target	QUAL=1	STX8	intron	STX8:ENST00000306357:intron_variant:MODIFIER:exon4/7:c.324-14595_324-14594insG::,STX8:ENST00000574431:intron_variant:MODIFIER:exon3/6:c.-10-14595_-10-14594insG::	regulatory_region_variant:promoter_flanking_region				L2c (LINE/L2)	rs374230429	0.8940	0.8547	11327,.							16.37						0		n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					STX8 (inh=n/a oe_syn=0.81 oe_mis=1.11 oe_lof=0.79)
chr17	10265419	10265419	C	T	0.1845	106	0.0000	43	off-target	QUAL=85	MYH13	intron	MYH13:ENST00000252172:intron_variant:MODIFIER:exon5/40:c.505+16G>A::,MYH13:ENST00000418404:intron_variant:MODIFIER:exon4/40:c.505+16G>A::					MamTip2 (DNA/hAT-Tip100)							-0.6160			0.01,0.13	8.62						0		0	0						MYH13 (inh=n/a oe_syn=0.99 oe_mis=0.98 oe_lof=0.74)
chr17	17965051	17965051	C	G	0.1810	224	0.0000	21	off-target	QUAL=70	GID4	intron	GID4:ENST00000268719:intron_variant:MODIFIER:exon4/5:c.709-108C>G::					L3 (LINE/CR1)							-0.3980			0.01,0.12	3.51						0		0	0						GID4 (inh=n/a oe_syn=0.69 oe_mis=0.49 oe_lof=0.08)
chr17	38548546	38548546	C	T	0.1671	391	0.0000	194		QUAL=173	TOP2A	missense	TOP2A:ENST00000423485:missense_variant:MODERATE:exon31/35:c.4012G>A:p.Asp1338Asn:		126430 [TOP2A DNA topoisomerase II,resistance to inhibition of,by amsacrine];										0.8330	T(0.22)	B(0.02)	0.38,0.97	22.80	0.04					0		0	0						TOP2A (inh=n/a oe_syn=0.84 oe_mis=0.58 oe_lof=0.18)
chr17	40879772	40879772	C	T	0.1651	329	0.0000	114		QUAL=132	EZH1	missense,5'UTR	EZH1:ENST00000415827:missense_variant:MODERATE:exon4/21:c.127G>A:p.Val43Met:PF11616,EZH1:ENST00000428826:missense_variant:MODERATE:exon4/21:c.127G>A:p.Val43Met:PF11616,EZH1:ENST00000435174:5_prime_UTR_variant:MODIFIER:exon4/19:c.-50G>A::,EZH1:ENST00000585893:missense_variant:MODERATE:exon4/20:c.127G>A:p.Val43Met:PF11616,EZH1:ENST00000590078:5_prime_UTR_variant:MODIFIER:exon3/20:c.-84G>A::,EZH1:ENST00000592743:missense_variant:MODERATE:exon3/20:c.127G>A:p.Val43Met:PF11616												2.2190	T(0.13),T(0.12), ,T(0.12), ,T(0.12)	P(0.45),B(0.02), ,B(0.01), ,B(0.02)	0.77,0.98	22.30	0.24					0		0	0						EZH1 (inh=n/a oe_syn=0.77 oe_mis=0.42 oe_lof=0.26)
chr17	57738715	57738715	A	G	0.1451	258	0.0000	35	off-target	QUAL=77	CLTC	intron	CLTC:ENST00000269122:intron_variant:MODIFIER:exon7/31:c.1168-89A>G::,CLTC:ENST00000393043:intron_variant:MODIFIER:exon7/30:c.1168-89A>G::,CLTC:ENST00000579456:intron_variant:MODIFIER:exon3/13:c.300+13907A>G::		118955 [CLTC Mental retardation,autosomal dominant 56,617854,Autosomal dominant];										-0.0020			0.26,0.90	15.25						0		0	0						CLTC (inh=AD oe_syn=0.86 oe_mis=0.27 oe_lof=0.03)
chr17	57738716	57738716	G	A	0.1465	276	0.0000	37	off-target	QUAL=79	CLTC	intron	CLTC:ENST00000269122:intron_variant:MODIFIER:exon7/31:c.1168-88G>A::,CLTC:ENST00000393043:intron_variant:MODIFIER:exon7/30:c.1168-88G>A::,CLTC:ENST00000579456:intron_variant:MODIFIER:exon3/13:c.300+13908G>A::		118955 [CLTC Mental retardation,autosomal dominant 56,617854,Autosomal dominant];										0.4830			0.07,0.79	14.83						0		0	0						CLTC (inh=AD oe_syn=0.86 oe_mis=0.27 oe_lof=0.03)
chr18	3457864	3457864	G	T	0.1127	2081	0.0000	243		QUAL=162	TGIF1	stop_gained	TGIF1:ENST00000330513:stop_gained:HIGH:exon3/3:c.1132G>T:p.Gly378Ter:,TGIF1:ENST00000343820:stop_gained:HIGH:exon3/3:c.745G>T:p.Gly249Ter:,TGIF1:ENST00000345133:stop_gained:HIGH:exon3/3:c.685G>T:p.Gly229Ter:,TGIF1:ENST00000400167:stop_gained:HIGH:exon3/3:c.685G>T:p.Gly229Ter:,TGIF1:ENST00000401449:stop_gained:HIGH:exon4/4:c.685G>T:p.Gly229Ter:,TGIF1:ENST00000405385:stop_gained:HIGH:exon3/3:c.685G>T:p.Gly229Ter:,TGIF1:ENST00000407501:stop_gained:HIGH:exon4/4:c.745G>T:p.Gly249Ter:,TGIF1:ENST00000472042:stop_gained:HIGH:exon2/2:c.685G>T:p.Gly229Ter:,TGIF1:ENST00000548489:stop_gained:HIGH:exon3/3:c.787G>T:p.Gly263Ter:,TGIF1:ENST00000551541:stop_gained:HIGH:exon3/3:c.685G>T:p.Gly229Ter:	regulatory_region_variant:promoter	602630 [TGIF1 Holoprosencephaly 4,142946,Autosomal dominant];										9.4180			0.97,0.96	44.00					COSM4733414,COSM4733415	0		0	0						TGIF1 (inh=AD oe_syn=1.07 oe_mis=0.95 oe_lof=0.43)
chr18	38530170	38530170	C	T	0.2439	42	0.0000	16	depth-nor;off-target	QUAL=54		intergenic	::intergenic_variant:MODIFIER::::					(TCTT)n (Simple_repeat)							0.0380			0.00,0.05	0.10						0		0	0						 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)
chr19	5215497	5215497	G	A	0.2886	385	0.0000	34		QUAL=91	PTPRS	intron	PTPRS:ENST00000262963:intron_variant:MODIFIER:exon23/33:c.4134+12C>T::,PTPRS:ENST00000348075:intron_variant:MODIFIER:exon22/32:c.4080+12C>T::,PTPRS:ENST00000353284:intron_variant:MODIFIER:exon18/28:c.2853+12C>T::,PTPRS:ENST00000357368:intron_variant:MODIFIER:exon27/37:c.4194+12C>T::,PTPRS:ENST00000372412:intron_variant:MODIFIER:exon27/37:c.4197+12C>T::,PTPRS:ENST00000587303:intron_variant:MODIFIER:exon26/36:c.4194+12C>T::,PTPRS:ENST00000588012:intron_variant:MODIFIER:exon21/31:c.4080+12C>T::,PTPRS:ENST00000592099:intron_variant:MODIFIER:exon17/27:c.2853+12C>T::												1.1780			0.01,0.18	9.78						0		0	0						PTPRS (inh=n/a oe_syn=1.23 oe_mis=0.69 oe_lof=0.13)
chr19	7119480	7119480	G	T	0.0151	1891	0.0000	182	freq-tum	QUAL=93	INSR	synonymous	INSR:ENST00000302850:synonymous_variant:LOW:exon21/22:c.3774C>A:p.Pro1258=:PF07714,INSR:ENST00000341500:synonymous_variant:LOW:exon20/21:c.3738C>A:p.Pro1246=:PF07714		147670 [INSR Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549/Hyperinsulinemic hypoglycemia,familial,5,609968,Autosomal dominant/Leprechaunism,246200,Autosomal recessive/Rabson-Mendenhall syndrome,262190,Autosomal recessive];										-6.8200			0.02,0.20	4.50						1	ARO-16	0	0						INSR (inh=AR+AD oe_syn=1.06 oe_mis=0.61 oe_lof=0.32)
chr19	7166435	7166435	G	A	0.1730	962	0.0000	98		QUAL=123	INSR	intron	INSR:ENST00000302850:intron_variant:MODIFIER:exon7/21:c.1611-20C>T::,INSR:ENST00000341500:intron_variant:MODIFIER:exon7/20:c.1611-20C>T::		147670 [INSR Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549/Hyperinsulinemic hypoglycemia,familial,5,609968,Autosomal dominant/Leprechaunism,246200,Autosomal recessive/Rabson-Mendenhall syndrome,262190,Autosomal recessive];										-0.8600			0.01,0.10	2.26		6.21>6.11				0		0	0						INSR (inh=AR+AD oe_syn=1.06 oe_mis=0.61 oe_lof=0.32)
chr19	11136857	11136857	C	T	0.6212	66	0.0000	11	depth-nor;off-target	QUAL=24	SMARCA4	intron	SMARCA4:ENST00000344626:intron_variant:MODIFIER:exon22/34:c.3169-119C>T::,SMARCA4:ENST00000358026:intron_variant:MODIFIER:exon22/35:c.3169-119C>T::,SMARCA4:ENST00000413806:intron_variant:MODIFIER:exon21/32:c.3169-119C>T::,SMARCA4:ENST00000429416:intron_variant:MODIFIER:exon23/35:c.3169-119C>T::,SMARCA4:ENST00000444061:intron_variant:MODIFIER:exon23/34:c.3169-119C>T::,SMARCA4:ENST00000450717:intron_variant:MODIFIER:exon21/32:c.3169-119C>T::,SMARCA4:ENST00000541122:intron_variant:MODIFIER:exon23/34:c.3169-119C>T::,SMARCA4:ENST00000589677:intron_variant:MODIFIER:exon23/34:c.3169-119C>T::,SMARCA4:ENST00000590574:intron_variant:MODIFIER:exon22/33:c.3169-119C>T::		603254 [SMARCA4 Coffin-Siris syndrome 4,614609,Autosomal dominant/Rhabdoid tumor predisposition syndrome 2,613325,Autosomal dominant];				rs1019193	0.1655	0.1889	646,.			-1.1820			0.03,0.10	0.18						1	I17R006	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					SMARCA4 (inh=AD oe_syn=1.11 oe_mis=0.40 oe_lof=0.01)
chr19	13050003	13050003	C	T	0.1215	974	0.0000	150		QUAL=125	CALR	synonymous	CALR:ENST00000316448:synonymous_variant:LOW:exon2/9:c.147C>T:p.Phe49=:PF00262	regulatory_region_variant:promoter	109091 [CALR Myelofibrosis,somatic,254450/Thrombocythemia,somatic,187950];										-0.5590			0.06,0.32	14.00						0		0	0						CALR (inh=AD oe_syn=1.35 oe_mis=0.91 oe_lof=0.15)
chr19	38948061	38948061	C	T	0.1958	529	0.0000	24	off-target	QUAL=76	RYR1	intron	RYR1:ENST00000355481:intron_variant:MODIFIER:exon16/104:c.1792-76C>T::,RYR1:ENST00000359596:intron_variant:MODIFIER:exon16/105:c.1792-76C>T::,RYR1:ENST00000360985:intron_variant:MODIFIER:exon16/104:c.1792-76C>T::		180901 [RYR1 Central core disease,117000,Autosomal recessive,Autosomal dominant/King-Denborough syndrome,145600,Autosomal dominant/Malignant hyperthermia susceptibility 1,145600,Autosomal dominant/Minicore myopathy with external ophthalmoplegia,255320,Autosomal recessive/Neuromuscular disease,congenital,with uniform type 1 fiber,117000,Autosomal recessive,Autosomal dominant];				rs1224406581						-0.0290			0.03,0.12	12.52						0		0	0						RYR1 (inh=AR+AD oe_syn=1.06 oe_mis=0.88 oe_lof=0.38)
chr19	39017614	39017614	C	T	0.1575	424	0.0000	55		QUAL=92	RYR1,AC067969.1	intron,non_coding_transcript_exon	RYR1:ENST00000355481:intron_variant:MODIFIER:exon70/104:c.10612-19C>T::,RYR1:ENST00000359596:intron_variant:MODIFIER:exon71/105:c.10627-19C>T::,RYR1:ENST00000360985:intron_variant:MODIFIER:exon71/104:c.10627-19C>T::,AC067969.1:ENST00000597015:non_coding_transcript_exon_variant:MODIFIER:exon3/3:n.550G>A::		180901 [RYR1 Central core disease,117000,Autosomal recessive,Autosomal dominant/King-Denborough syndrome,145600,Autosomal dominant/Malignant hyperthermia susceptibility 1,145600,Autosomal dominant/Minicore myopathy with external ophthalmoplegia,255320,Autosomal recessive/Neuromuscular disease,congenital,with uniform type 1 fiber,117000,Autosomal recessive,Autosomal dominant];										-0.2580			0.03,0.14	4.39		9.67>9.64				0		0	0						RYR1 (inh=AR+AD oe_syn=1.06 oe_mis=0.88 oe_lof=0.38), AC067969.1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)
chr19	39061282	39061282	C	T	0.1777	1703	0.0000	142		QUAL=163	RYR1	synonymous	RYR1:ENST00000355481:synonymous_variant:LOW:exon93/105:c.13680C>T:p.Phe4560=:PF06459,RYR1:ENST00000359596:synonymous_variant:LOW:exon94/106:c.13695C>T:p.Phe4565=:PF06459,RYR1:ENST00000360985:synonymous_variant:LOW:exon93/105:c.13680C>T:p.Phe4560=:PF06459		180901 [RYR1 Central core disease,117000,Autosomal recessive,Autosomal dominant/King-Denborough syndrome,145600,Autosomal dominant/Malignant hyperthermia susceptibility 1,145600,Autosomal dominant/Minicore myopathy with external ophthalmoplegia,255320,Autosomal recessive/Neuromuscular disease,congenital,with uniform type 1 fiber,117000,Autosomal recessive,Autosomal dominant];				rs751989788		0.0001		0.0000,0.0000,0.0000,0.0001,0.0000		0.2260			0.65,0.97	9.12						0		0	0						RYR1 (inh=AR+AD oe_syn=1.06 oe_mis=0.88 oe_lof=0.38)
